Premium
Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia
Author(s) -
Guardiola Philippe,
Kuentz Mathieu,
Garban Frédéric,
Blaise Didier,
Reiffers Josy,
Attal Michel,
Buzyn Agnès,
Lioure Bruno,
Bordigoni Pierre,
Fegueux Nathalie,
Tanguy MarieLaure,
Vernant JeanPaul,
Gluckman Eliane,
Socié Gérard
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02306.x
Subject(s) - medicine , transplantation , surgery , gastroenterology , stem cell , serology , cytomegalovirus , immunology , viral disease , herpesviridae , human immunodeficiency virus (hiv) , antibody , genetics , biology
In this retrospective multicentre study, we analysed the results of 82 consecutive second early allogeneic transplants for primary ( n = 28) or secondary ( n = 54) graft failures performed between 1985 and 1997 in patients with acute leukaemia ( n = 33), aplastic anaemia ( n = 29) or chronic myeloid leukaemia ( n = 20). HLA‐matched siblings were used in 64 cases. The same donors were used for both transplants in 56 cases and the first transplant was T‐cell depleted in 30 cases. The median age at transplant was 25 years and the median intertransplant time interval was 2 months. Estimates of the 3‐year overall survival and day 100 transplant‐related mortality were 30% and 53% respectively. A recipient age < 34 years at transplant, an intertransplant time interval ≥ 80 d and a positive recipient cytomegalovirus serology were predictors of a better outcome. The use of cyclosporin A (CsA) after second transplant had a dramatic impact on outcome, the best results being observed with CsA alone. The day 40 probability of neutrophil recovery was 73%. The use of peripheral blood progenitor cells (PBPCs) was associated with a higher and faster neutrophil recovery. Other factors associated with neutrophil recovery were an intertransplant time interval ≥ 80 d and a positive recipient cytomegalovirus serology. Therefore, second early allogeneic transplantation for graft failure is an effective treatment, especially if patients can receive CsA for graft‐versus‐host disease prevention and are retransplanted more than 80 d from first transplant.